Denis Nash

Denis Nash

Auto-generated profile, based on publicly available information

Denis Nash

CUNY Institute for Implementation Science in Population Health, City University of New York, New York, NY, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2020 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
AEAdrienne Epstein
Adrienne Epstein
EBEran Bendavid
Eran Bendavid
DNDenis Nash
Denis Nash
ECEdwin D. Charlebois
Edwin D. Charlebois
SWSheri D Weiser
Sheri D Weiser
Drought has many known deleterious impacts on human health, but little is known about the relationship between drought and intimate partner violence (IPV). We aimed to evaluate this relationship and to assess effect heterogeneity between population subgroups among women in 19 sub-Saharan African countries. We used data from 19 Demographic and Health Surveys from 2011 to 2018 including 83,990 partnered women aged 15–49 years. Deviations in rainfall in the year before the survey date were measured relative to the 29 previous years using Climate Hazards Group InfraRed Precipitation with Station data, with recent drought classified as ordinal categorical variable (severe: ≤10th percentile; mild/moderate: >10th percentile to ≤30th percentile; none: >30th percentile). We considered 4 IPV-related outcomes: reporting a controlling partner (a risk factor for IPV) and experiencing emotional violence, physical violence, or sexual violence in the 12 months prior to survey. Logistic regression was used to estimate marginal risk differences (RDs). We evaluated the presence of effect heterogeneity by age group and employment status. Of the 83,990 women included in the analytic sample, 10.7% (9,019) experienced severe drought and 23.4% (19,639) experienced mild/moderate drought in the year prior to the survey, with substantial heterogeneity across countries. The mean age of respondents was 30.8 years (standard deviation 8.2). The majority of women lived in rural areas (66.3%) and were married (73.3%), while less than half (42.6%) were literate. Women living in severe drought had higher risk of reporting a controlling partner (marginal RD in percentage points = 3.0, 95% CI 1.3, 4.6; p < 0.001), experiencing physical violence (marginal RD = 0.8, 95% CI 0.1, 1.5; p = 0.019), and experiencing sexual violence (marginal RD = 1.2, 95% CI 0.4, 2.0; p = 0.001) compared with women not experiencing drought. Women living in mild/moderate drought had higher risk of reporting physical (marginal RD = 0.7, 95% CI 0.2, 1.1; p = 0.003) and sexual violence (marginal RD = 0.7, 95% CI 0.3, 1.2; p = 0.001) compared with those not living in drought. We did not find evidence for an association between drought and emotional violence. In analyses stratified by country, we found 3 settings where drought was protective for at least 1 measure of IPV: Namibia, Tanzania, and Uganda. We found evidence for effect heterogeneity (additive interaction) for the association between drought and younger age and between drought and employment status, with stronger associations between drought and IPV among adolescent girls and unemployed women. This study is limited by its lack of measured hypothesized mediating variables linking drought and IPV, prohibiting a formal mediation analysis. Additional limitations include the potential for bias due to residual confounding and potential non-differential misclassification of the outcome measures leading to an attenuation of observed associations. Our findings indicate that drought was associated with measures of IPV towards women, with larger positive associations among adolescent girls and unemployed women. There was heterogeneity in these associations across countries. Weather shocks may exacerbate vulnerabilities among women in sub-Saharan Africa. Future work should further evaluate potential mechanisms driving these relationships.

21 December 2022 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
MRMcKaylee M Robertson
McKaylee M Robertson
SQSaba A Qasmieh
Saba A Qasmieh
SKSarah G Kulkarni
Sarah G Kulkarni
CTChloe A Teasdale
Chloe A Teasdale
HJHeidi E Jones
Heidi E Jones
DNDenis Nash
Denis Nash
Background: We estimated the prevalence of long COVID and impact on daily living among a representative sample of adults in the United States. Methods: We conducted a population-representative survey, 30 June–2 July 2022, of a random sample of 3042 US adults aged 18 years or older and weighted to the 2020 US population. Using questions developed by the UK's Office of National Statistics, we estimated the prevalence of long COVID, by sociodemographics, adjusting for gender and age. Results: An estimated 7.3% (95% confidence interval: 6.1–8.5%) of all respondents reported long COVID, corresponding to approximately 18 828 696 adults. One-quarter (25.3% [18.2–32.4%]) of respondents with long COVID reported their day-to-day activities were impacted “a lot” and 28.9% had severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection more than 12 months ago. The prevalence of long COVID was higher among respondents who were female (adjusted prevalence ratio [aPR]: 1.84 [1.40–2.42]), had comorbidities (aPR: 1.55 [1.19–2.00]), or were not (vs were) boosted (aPR: 1.67 [1.19–2.34]) or not vaccinated (vs boosted) (aPR: 1.41 [1.05–1.91]). Conclusions: We observed a high burden of long COVID, substantial variability in prevalence of SARS-CoV-2, and risk factors unique from SARS-CoV-2 risk, suggesting areas for future research. Population-based surveys are an important surveillance tool and supplement to ongoing efforts to monitor long COVID.

23 February 2022 in The Lancet HIV
Verified
Journal Article
Closed access
AJAmy C. Justice
Amy C. Justice
MGMatthew B Goetz
Matthew B Goetz
CSCameron N Stewart
Cameron N Stewart
BHBrenna C Hogan
Brenna C Hogan
EHElizabeth Humes
Elizabeth Humes
KAKeri N Althoff
Keri N Althoff

1 October 2021 in The Journal of Pediatrics
Verified
Journal Article
Closed access
CTChloe A. Teasdale
Chloe A. Teasdale
LBLuisa N. Borrell
Luisa N. Borrell
SKSpencer Kimball
Spencer Kimball
MRMichael L. Rinke
Michael L. Rinke
MRMadhura Rane
Madhura Rane
DNDenis Nash
Denis Nash

1 August 2021 in Vaccine
Verified
Journal Article
Closed access
CTChloe A. Teasdale
Chloe A. Teasdale
LBLuisa N. Borrell
Luisa N. Borrell
YSYanhan Shen
Yanhan Shen
SKSpencer Kimball
Spencer Kimball
MRMichael L. Rinke
Michael L. Rinke
DNDenis Nash
Denis Nash

10 June 2019 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
OTOlga Tymejczyk
Olga Tymejczyk
EBEllen Brazier
Ellen Brazier
CYConstantin Yiannoutsos
Constantin Yiannoutsos
MVMichael Vinikoor
Michael Vinikoor
MLMonique van Lettow
Monique van Lettow
ICIeDEA consortium
IeDEA consortium
Most countries have formally adopted the World Health Organization’s 2015 recommendation of universal HIV treatment (“treat all”). However, there are few rigorous assessments of the real-world impact of treat all policies on antiretroviral treatment (ART) uptake across different contexts. We used longitudinal data for 814,603 patients enrolling in HIV care between 1 January 2004 and 10 July 2018 in 6 countries participating in the global International epidemiology Databases to Evaluate AIDS (IeDEA) consortium: Burundi (N = 11,176), Kenya (N = 179,941), Malawi (N = 84,558), Rwanda (N = 17,396), Uganda (N = 96,286), and Zambia (N = 425,246). Using a quasi-experimental regression discontinuity design, we assessed the change in the proportion initiating ART within 30 days of enrollment in HIV care (rapid ART initiation) after country-level adoption of the treat all policy. A modified Poisson model was used to identify factors associated with failure to initiate ART rapidly under treat all. In each of the 6 countries, over 60% of included patients were female, and median age at enrollment ranged from 32 to 36 years. In all countries studied, national adoption of treat all was associated with large increases in rapid ART initiation. Significant increases in rapid ART initiation immediately after treat all policy adoption were observed in Rwanda, from 44.4% to 78.9% of patients (34.5 percentage points [pp], 95% CI 27.2 to 41.7; p < 0.001), Kenya (25.7 pp, 95% CI 21.8 to 29.5; p < 0.001), Burundi (17.7 pp, 95% CI 6.5 to 28.9; p = 0.002), and Malawi (12.5 pp, 95% CI 7.5 to 17.5; p < 0.001), while no immediate increase was observed in Zambia (0.4 pp, 95% CI −2.9 to 3.8; p = 0.804) and Uganda (−4.2 pp, 95% CI −9.0 to 0.7; p = 0.090). The rate of rapid ART initiation accelerated sharply following treat all policy adoption in Malawi, Uganda, and Zambia; slowed in Kenya; and did not change in Rwanda and Burundi. In post hoc analyses restricted to patients enrolling under treat all, young adults (16–24 years) and men were at increased risk of not rapidly initiating ART (compared to older patients and women, respectively). However, rapid ART initiation following enrollment increased for all groups as more time elapsed since treat all policy adoption. Study limitations include incomplete data on potential ART eligibility criteria, such as clinical status, pregnancy, and enrollment CD4 count, which precluded the assessment of rapid ART initiation specifically among patients known to be eligible for ART before treat all. Our analysis indicates that adoption of treat all policies had a strong effect on increasing rates of rapid ART initiation, and that these increases followed different trajectories across the 6 countries. Young adults and men still require additional attention to further improve rapid ART initiation.